Viking Therapeutics Inc. VKTX announced on Wednesday that it has initiated a Phase 1 trial evaluating VK3019, an ...
Partnering could be an option for Viking Therapeutics, although CEO Brian Lian, Ph.D., was unwilling to give away too much on any ongoing or previous discussions. (Nuthawut Somsuk/iStock/Getty Images ...
GlobalData on MSN
Viking Therapeutics commences Phase I trial of VK3019
Primary objectives involve assessing the tolerability, pharmacokinetics and safety of VK3019.
Hosted on MSN
Viking Therapeutics outlines dual Phase III obesity programs while advancing oral VK2735 and maintenance regimens
Brian Lian, President and CEO, highlighted several milestones in 2025, focusing on the obesity pipeline: "With the subcutaneous formulation of our lead molecule, VK2735, following the positive ...
I last updated on Viking Therapeutics, Inc. (VKTX) in October last year, covering the company's Q3 earnings and business updates, and issued stock with a Buy rating - my sixth straight Buy call, in ...
Pills that work similarly to currently available injectable medications represent the next wave of metabolic disorder drugs, and Viking Therapeutics is pushing its drug candidate to the forefront with ...
The MarketWatch News Department was not involved in the creation of this content. 78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity and Type 2 Diabetes SAN DIEGO, March 26, 2026 ...
SAN DIEGO, March 26, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results